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Human T-cell lymphotropic virus type I (HTLV-I) is a retrovirus that is the
causative agent of the fatal disease adult T-cell leukemia (ATL).  HTLV-I silently
infects over twenty million people worldwide; up to ten percent of these will
develop ATL in their lifetime.  There are currently no effective treatments for this
disease.
HTLV-I expresses its genome as polypeptides that must be processed in order to
produce infectious virions.  Like other retroviruses, HTLV-I encodes an aspartic
acid protease to process these polypeptides into mature form.  Because the
protease is essential in the virus life cycle, it is an attractive target for the
treatment of HTLV-I-induced ATL.
The present work examines the structure and function of HTLV-I protease.  A
theoretical structure of the protease is presented, and the function of the C-
terminal extension is considered.  In order to determine which residues are
involved in binding substrate, two experiments were performed:  first, several
residues were mutated to the corresponding residues in HIV-1 protease to
determine whether HTLV-I protease can be made to process an HIV-1 protease
substrate; second, an alanine scan was performed to knock out individual
residues to assess their importance in binding substrate.  This work builds
knowledge of the structure and function of HTLV-I protease.  By understanding
which residues play a role in binding substrate and by developing a clearer
picture of the structure of the protease, it will be possible to develop specific
inhibitors for HTLV-I protease.
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CHAPTER 1
HTLV-I:  AN ONCOGENIC RETROVIRUS
1.1 On viruses
Pathogenic diseases have plagued humankind since the beginning of
recorded history.  Although their cause was unknown until recent times, viral
diseases have played a significant role in historical events.  For example,
colonization of the Americas was affected by the spread of smallpox among
native populations.  Also, influenza epidemics have caused countless millions of
deaths.  Recent epidemic scares, in fact and fiction, center around newly
emerging viruses such as the coronavirus SARS, West Nile Virus, and the Ebola
virus.
The cause of illness was unknown until relatively modern times.  Until about
300 years ago in the Western world, diseases were considered acts of God, and
virulence or contagiousness were not widely understood or accepted.  Bacteria
were first observed by Anton van Leeuwenhoek in 1677.  The implication of
bacteria in illness was fully realized in the 19th century, and in 1876, studies of
anthrax, caused by Bacillus anthracis, led Robert Koch to develop postulates
describing pathogenic microorganisms (Baron, 1996).
A number of plants are affected by a disease that causes mosaic-like patterns
of normal color, light green and yellow on the leaves.  This disease stunts growth
and damages leaves, flowers and fruit of affected plants.  Studies by biologists
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revealed that certain cell-free extracts of plants with this disease could infect
other plants.  This work led to the discovery of the tobacco mosaic virus.  Later,
many other viruses were discovered and implicated in a number of plant, animal,
and human diseases (Fraenkel-Conrat, 1988).
Virus research is a leading field of medicinal chemistry.  While many
compounds have been discovered or prepared to combat bacterial and fungal
disease, few treatments have been developed for viral diseases aside from HIV,
and many of these treatments are intended to alleviate symptoms rather than
interrupt the virus life cycle.  The principal means of fighting viral infection is
preventive treatment with vaccines.
There has been debate whether viruses are either living or nonliving.  In a
sense, viruses are parasites; like mosquitoes, they rely on the resources of a
host in order to reproduce.  However, isolated virus particles are typically inert
and are not living in the sense that the mosquito carries on respiration and other
life processes independent of a host.  However, viruses have a self-replicating
genome and often produce enzymes in the host to assemble a mature virus,
blurring the line between whether they are living or nonliving (Voet, 1995).
1.2 Retroviruses
Retroviruses are virus particles whose genome is RNA-based and that
contain reverse transcriptase to transcribe the RNA genome into DNA. Most
organisms carry a linear or circular double-stranded DNA genome, and a number
of viruses also carry a single- or double-stranded DNA genome.  DNA serves as
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the template for cellular function through the classical central dogma of molecular
biology:  DNA is transcribed to RNA, which is translated to proteins that carry out
cellular functions, including copying DNA and RNA.  Retroviruses break this
paradigm:  RNA is reverse transcribed into DNA, which is inserted into the host
genome.  The viral genome then functions according to central dogma, but also
produces RNA copies of the genome that are used to assemble infectious
particles.  Further discoveries, such as catalytic RNA or “ribozymes” that imitate
enzyme or protein function, have also challenged the central dogma; however,
the retrovirus life cycle represents the first complete system that demonstrates
reversibility of the pathway (Voet, 1995).
In 1911, Peyton Rous demonstrated the existence of a pathogen present
in cell-free media that could induce tumors in chickens (Rous, 1911).  This
pathogen is now called the Rous sarcoma virus (RSV), and Rous received the
1966 Nobel Prize in Physiology or Medicine “for his discovery of tumour-inducing
viruses”.  RSV is a retrovirus, but Rous did not discover this.  The first retrovirus
to be identified was the feline leukemia virus, found in 1973 by W.D. Hardy et al.
(Hardy et al., 1973)  Other retroviral oncoviruses have also been found, including
the previously noted Rous sarcoma virus, equine infectious anemia virus (EIAV),
and bovine leukemia virus (BLV), which causes leukemia in cattle.
The first retrovirus found in humans was HTLV-I, isolated in 1980 by
Poiesz et al. (Poiesz et al., 1980) from patients with adult T-cell leukemia (ATL).
This discovery was eclipsed by Gallo and others, who discovered the retrovirus
HTLV-III (later called HIV) in 1983 (Gallo, 1996).  HTLV-I was later found in
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patients with HTLV-I associated myelopathy (HAM), tropical spastic paraparesis
(TSP) (Gessain et al., 1985), and other chronic diseases including arthritis,
infective dermatitis, and uveitis (Gessain, 1996). Studies have established that
HTLV-I can travel horizontally through a population by sexual contact or
intravenous drug use and vertically from mother to infant (Gallo, 1996).  At least
20 million people are infected with HTLV-I, primarily in Japan, the Caribbean,
sub-Saharan Africa, and the United States.  The Centers for Disease Control
have classified HTLV-I as a dangerous emerging pathogen.
1.3 Classification of retroviruses
Retroviruses are classified in the family Retroviridae.  All retroviruses have
an RNA genome, use reverse transcriptase to copy the genome, and are
membrane-bound.  Viral infection by certain members of this family can cause
malignant tumors and leukemia in animals and humans.  Other members of the
retrovirus family are immunodeficiency viruses, notably HIV, that attack cells of
the host immune system.  The International Committee on Taxonomy of Viruses
(ICTV) is responsible for standardized nomenclature and taxonomy of viruses
(Murphy, 1995).  The ICTV taxonomy charts are accessible online (ICTVdb,
http://www.ncbi.nlm.nih.gov/ICTVdb/).
HTLV-I is a member of family Retroviridae, which includes all viruses that
carry an RNA genome and utilize reverse transcriptase and integrase to insert
the genome into the host.  Further classification is based on several criteria,
including the pathology of the virus.  HTLV-I is classified in genus Deltaretrovirus,
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the members of which are tumorigenic. Other members of genus Deltaretrovirus
include bovine leukemia virus (BLV), HTLV-II, feline leukemia virus (FLV), and
simian T-lymphotropic virus 1.  The ICTV species name for HTLV-I is human T-
lymphotropic virus type 1.  HIV-1, in contrast, belongs to genus Lentivirus, which
is comprised of non-tumorigenic retroviruses; this is why it is no longer named its
initial classification, HTLV-III.  The tumorigenic and non-tumorigenic viruses also
differ structurally; tumorigenic viruses have a spherical capsid, while non-
tumorigenic viruses have a conical or cylindrical capsid.
1.4 A day in the life of a retrovirus:  structure, function, and replication
All retroviruses have a similar genomic structure.  Retroviruses express three
principal polypeptides:  one encoding structural proteins, one encoding DNA- and
RNA-manipulating enzymes, and one encoding envelope proteins.  They also
encode regulatory proteins that control viral replication and define viral pathology.
All retroviruses follow a similar life cycle in terms of infection and replication.
The retroviral genome expresses three principal polypeptides.  The first,
called group antigen or Gag, contains proteins that make up the internal structure
of the mature virion:  the matrix, capsid, and nucleocapsid.  An aspartic acid
protease is encoded at the C-terminal end of Gag.  The second polypeptide,
polymerase or Pol, contains reverse transcriptase, the enzyme needed to
transcribe the viral RNA genome, and integrase, which splices the viral DNA into
the host genome.  The third polyprotein, envelope or Env, contains two envelope
proteins.  The envelope proteins are on the exterior of the mature virus and are
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involved in recognizing receptors on the surface of target cells and beginning the
infection process.
Also encoded among these viral polypeptides, usually as part of the structural
proteins, is a protease, an enzyme that processes viral polypeptides into mature,
active form. The envelope polyprotein is processed by a pathway that is not fully
understood.  It is known that Env is processed by an endopeptidase and
glycosylated by a native cellular pathway (Coffin, Hughes, and Varmus, 1997).
1.5 HTLV-I specific structure and function
HTLV-I virus particles are spherical and membrane-enclosed and range
from 80-100 nm in diameter.  The structure of a typical HTLV-I particle is
depicted in Figure 1.1.  The membrane is derived from host cells, but it also
contains virally encoded transmembrane protein (TM) and surface unit
glycoprotein (SU).  The core of the viral particle is composed of matrix, capsid,
and nucleocapsid protein and contains two copies of the viral RNA genome and
one copy each of reverse transcriptase and integrase.  A copy of tRNA-Pro, also
present in the capsid, initiates reverse transcription in the host (Murphy, 1995).
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Figure 1.1.  Organization of HTLV-I virion.  Virus membrane (yellow) contains
glycoproteins TM (transmembrane protein, red) and SU (surface unit, blue).
Virus particle is made of matrix (MA, orange) surrounding cone- or cylinder-
shaped capsid (CA, red cylinder).  Capsid contains two copies of genomic RNA
(silver helices) associated with nucleocapsid (NC, black spheres).  Capsid also
contains reverse transcriptase (RT, green cube) and integrase (IN, red diamond).
A copy of tRNA-Pro (stack of blue spheres) is present and initiates reverse
transcription of the viral genome.
The HTLV-I viral genome is 9032 base pairs long and encodes three
genes in three open reading frames: gag, pol, and env.  These genes are
contained between long terminal repeats (LTR's).  HTLV-I's genome organization
is depicted in Figure 1.2.  The first set of genes includes gag, pro, and pol.  The
genes pro and pol are frameshifted –1, or one base in the 5’ direction, relative to
the preceding gene.  The genes env, rex, and tax are separate  from the gag-pro-
pol complex in the 3’ direction.
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Figure 1.2.  HTLV-I genome, showing genes and open reading frame.
HTLV-I expresses structural and replicative components as three
polyproteins:  Gag, Gag-Pro, and Gag-Pro-Pol.  Gag-Pro and Gag-Pro-Pol are
produced by ribosomal slippage (Nam et al., 1993; Nam et al., 1988), allowing
the production of what are effectively truncated versions of the full-length
polyprotein.  The expressed products are cleaved by an aspartic acid protease
also encoded in the viral genome.  Gag (48 kDa) is processed into matrix (MA),
capsid (CA), and nucleocapsid (NC) peptides.  Cleavage of Pol (99 kDa) yields
reverse transcriptase (RT), which transcribes viral RNA to DNA, and integrase
(IN), which integrates viral RNA into the host.  The protease (PR) is encoded
between gag and pol in a different reading frame.  The amino acid sequence of
Gag-Pro-Pol is shown in Figure 1.3, colored to indicate the different protein
components.






































Figure 1.3.  Complete translation of HTLV-I gag-pro-pol polyprotein:  matrix,
capsid, nucleocapsid, protease, reverse transcriptase,
integrase.  Uncolored sequences are linker regions with no known function.
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Env is expressed independently from the Gag-Pro-Pol complex.  Cleavage
of Env yields two membrane (envelope) proteins, the transmembrane protein
(TM) and the surface glycoprotein (SU).  The regulatory proteins rex and tax are
encoded in the same reading frame as Env.
One mode of replication of HTLV-I is similar to other retroviruses,
including HIV (Morrow, Park, and Wakefield, 1994).  Virus infection occurs
through binding of a virus surface protein to a T-cell receptor.  The virus particle
enters the cell and the RNA genome is copied to double-stranded DNA by
reverse transcriptase.  The viral DNA is integrated into the host DNA.  The 5'
LTR, upon activation by rex and tax regulatory proteins, promotes transcription of
the viral genome.  Translated polyproteins are processed into mature form by the
viral protease.  The function of the protease is depicted in Figure 1.4.
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Figure 1.4.  Action of HTLV-I protease in viral maturation.  Gag polyprotein is
cleaved into structural proteins matrix (MA), capsid (CA), and nucleocapsid (NC),
while Pol polyprotein is cleaved into genome-processing proteins reverse
transcriptase (RT) and integrase (IN).
Mature viral proteins and the transcribed viral RNA genome assemble
near the cell membrane.  The virus core acquires a lipid bilayer containing virally
expressed surface proteins from the host cell membrane as it buds into a





Figure 1.5.  HTLV-I replication cycle. The virus particle (yellow sphere, top left)
binds receptors of the cell surface and its membrane fuses with the cell
membrane.  The genomic RNA (dark green single strand) and reverse
transcriptase (RT, green square) are inserted into the cell.  RT transcribes the
RNA genome to double-stranded DNA (light green) and, with integrase (red
diamond), enters the nucleus (blue sphere, left).  The virus genome is inserted
into the host DNA by integrase, and regulatory proteins rex and tax are
expressed.  Tax re-enters the nucleus and binds the 5’ LTR of the viral genome,
triggering transcription of the genome, structural proteins, and replicative
enzymes.  The gag-pro-pol complex and env are expressed (right side); the
protease (PR, blue square) processes gag-pro-pol into active form, and the virus
proteins and genome assemble with env products at the cell membrane (top
right).  The completed virus buds from the cell, taking part of the cell membrane
as part of its shell.
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HTLV-I propagates by another method that occurs more frequently in vivo
compared to the described process of particle formation.  David Derse et al.
(Derse et al., 2001) demonstrated that, while it is possible to generate virions in
vitro, very few (as low as 1 in 10,000) are infectious.  Indeed, cell-free
transfusions seem to pose little risk.  It is therefore more likely that HTLV-I
spreads by cell-to-cell contact.  This is supported by the observations of Igakura
et al. (Igakura et al., 2003), who showed that HTLV-I can polarize the cell
membrane of lymphocytes.  Lymphocytes have a polarization mechanism that
facilitates presentation of antigens.  Virus-induced polarization leverages this
system to assemble viral proteins and form a synapse between cells by which
the virus is transferred.  Other work has shown that virions need not be present
to induce tumor formation.  Transformation with the tax regulatory protein alone
causes tumorigenesis (Grossman et al., 1995), though a means of introducing
the tax gene into the cellular genome is still required.  However, the protease is
still necessary for viral maturation leading to the propagation of cell infection.
1.6 Pathology and treatment
HTLV-I has been shown to be the causative agent of ATL.  On the cellular
level, HTLV-I infection causes overexpression of IL-2 receptors, which bind IL-2,
the T-cell specific growth factor (Wong-Staal and Gallo, 1985).  Clinically, ATL
manifests in several forms, linked by serologic analysis confirming presence of
HTLV-I genes or gene products.  The principal form of ATL manifests with
hypercalcemia, lymphadenopathy, lymphomatous meningitis, involvement of the
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liver or spleen, dermal involvement, and lytic bone lesions (Hjelle, 1991).  This
form is aggressive, with life expectancy of 6-18 months following emergence of
symptoms.  Patients with HTLV-I infection have also been characterized with
non-Hodgkin’s lymphoma, “smoldering” ATL with normal blood cell count but
prominent skin lesions, and isolated T-cell cutaneous lymphoma.
Two other closely related conditions, HAM and TSP, are associated with
HTLV-I infection.  These neurological disorders are characterized by HTLV-I-
specific T cell clones in the blood and spinal fluid.  These disorders are
progressive, with symptoms including sensory disturbance, muscle weakness in
the extremities, urinary dysfunction, muscle spasticity, and hyper-reflexia (Hoger
et al., 1997).
No specific treatments for HTLV-I have been approved.  There have been
several reports on the use of HIV-1 reverse transcriptase inhibitors to impair viral
replication, but these are not an effective treatment option.  There are literature
reports of tests of HTLV-I protease inhibitors in vitro by Ding et al., Akaji et al.,
and others (Akaji, Teruya, and Aimoto, 2003; Ding, Rich, and Ikeda, 1998), but
no cell-based assays or clinical trials have yet been reported.
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HTLV-I PROTEASE:  A RETROVIRAL PROTEASE
2.1 Proteases
Enzymes are proteins that are able to catalyze biologically important
reactions.  Proteases are enzymes that are able to catalyze the cutting of other
proteins.  Proteases serve a number of functions in organisms, including the
breakdown of proteins as part of digestion, for example, trypsin and pepsin.
Other proteases cleave inactive precursor proteins to form the active protein.  For
example, as part of the blood clotting mechanism, thrombin cleaves a specific
peptide bond in fibrinogen, forming fibrin (Voet, 1995).
2.2 Classification of proteases
The Nomenclature Committee of the International Union of Biochemistry
and Molecular Biology classifies proteases in subgroup 4 of the hydrolases group
of enzymes.  Proteases in the subclass are further divided into families based on
the type of reaction that is catalyzed, active site residues, and evolutionary
relation in terms of sequence and structure (Rao et al., 1998).
Proteases are collected in an online database called MEROPS (Rawlings,
O'Brien, and Barrett, 2002).  In this system, proteases are classified by active site
residue, clan, and family.  Top-level classification of proteases is based on the
catalytic group.  Most known proteases utilize either an aspartic acid, serine,
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cysteine, or bound metal ion or metalloprotease; however, there is a fifth group,
proteases of mixed or unknown active site.  Clan grouping of proteases is based
on apparent evolutionary origin.  In the case of HTLV-I protease, the protease
sequence is thought to be derived from a pepsin-like aspartic acid protease
ancestor.  Therefore, it is placed in clan AA with pepsin, retropepsin, and
pararetrovirus proteases.  However, while these three representative proteases
have evolutionary relation, they vary significantly in sequence and structure and
are classified into separate families.  Pepsin is classified in family A1, a family
whose members have aspartic acid as the catalytic residue and which are
monomers with two lobes, each with a catalytic aspartic acid.  Retroviral
proteases are members of the A2 family.  Members of this family are structurally
similar to pepsin with two lobes, but they are homodimers.  The two monomers,
each with one active aspartic acid, dimerize to form the active bilobed structure
(Rawlings and Barrett, 1995).  A significant difference between A1 and A2
families is that A2 family proteases are sequentially identical dimers, while the
monomers of A1 family proteases have topologically similar lobes that do not
have identical sequence.
The structures of several A2-family proteases have been determined
experimentally.  The first retroviral protease to be crystallized was RSV protease,
in 1988 (Miller, Leis, and Wlodawer, 1988), while HIV-1 protease is perhaps the
most widely studied, with some 200 structures of various mutants and inhibitor
complexes reported to date (HIVdb, http://mcl1.ncifcrf.gov/hivdb/index.html).  The
structures of HIV-1 protease (PDB:1D4L) (Tyndall et al., 2002), HIV-2 protease
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(PDB:1IDA) (Tong et al., 1993), simian immunodeficiency virus (SIV) protease
(PDB:1YTH) (Rose et al., 1996), feline immunodeficiency virus (FIV) protease
(PDB:4FIV) (Kervinen et al., 1998), Rous sarcoma virus (RSV) protease
(PDB:1BAI) (Wu et al., 1998), avian myeloblastosis associated virus (MAV)
protease (PDB:1MVP) (Ohlendorf et al., 1992), and equine infectious anemia
virus (EIAV) protease (PDB:1FMB) (Gustchina et al., 1996) have been
determined experimentally.  Representative structures of these retroviral
proteases, as well as a structure of pepsin (PDB:1PSO) (Sielecki et al., 1990),
are shown in Figure 2.1.  The structures of HTLV-I protease and related BLV
protease have not been experimentally determined.  Theoretical, computer-
generated models of HTLV-I protease have been reported ((Tözsér et al., 2000),
Shuker SB et al., PDB file 1O0J).
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Figure 2.1.  Structures of retroviral proteases.  1BAI, RSV protease, 1D4L, HIV-1 protease; 1FMB, EIAV protease; 1IDA,
HIV-2 protease; 1YTH, SIV protease; 4FIV, FIV protease; 1PSO, pepsin.  In 1FMB and 4FIV, only one chain of the
homodimer was stored in the PDB.  1BAI and 1YTH are shown with bound inhibitor.  (References in text)
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2.3 Aspartic acid proteases:  structure and mechanism
Retroviral protease structures follow a general template (Wlodawer and
Gustchina, 2000), which is depicted in Figure 2.2.  The secondary structure, from
N-terminal to C-terminal, consists of the following: three to four anti-parallel beta
sheets comprising a hairpin and a wide loop which contains the catalytic aspartic
acid, followed by a helical region, an anti-parallel pair of beta sheets that form a
hairpin observed as a flap, two to three anti-parallel beta sheets comprising a
hairpin and wide loop, a helical region, and terminal beta sheet.  The dimer
contains a single active site formed by residues from the two identical monomers,
a topology that is unique to retroviral proteases.
Figure 2.2.  Schematic of secondary structural elements in retroviral proteases.
Asterisk indicates position of catalytic aspartic acid.
The binding pockets of proteases correspond to amino acids in the
substrate.  There is a naming convention for binding sites and positions in the
substrate adopted from the work of Schechter and Berger (Schechter and
Berger, 1967; Schechter and Berger, 1968).  From N-terminal to C-terminal
*
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relative to the substrate, binding sites are named S4 to S4’, and positions on the
substrate are named P4 to P4’.  The bond that will be cleaved, the scissile bond,
is in the middle between P1 and P1’ in the substrate.  Figure 2.3 shows the
relation of substrate, binding sites, and scissile bond.
 Figure 2.3.  Schematic diagram of substrate positions and binding pockets.
Circles represent substrate amino acids, and arcs represent sites on the
protease.  The scissile bond is the point of cleavage.
Structural and computer studies of HIV-1 protease have suggested a
mechanism of catalysis (Liu, Muller-Plathe, and van Gunsteren, 1996).  The
mechanism is a general acid-base mechanism involving the two active aspartic
acid residues and water.  A tetrahedral intermediate is formed by water attacking
the carbon of the amide bond to be cleaved.  The conjugate base aspartate
abstracts a proton from the intermediate, restoring the carbonyl group and
displacing the nitrogen of the amide bond.  The nitrogen simultaneously abstracts

















































Figure 2.4.  Mechanism of aspartic acid proteases.
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2.4 HTLV-I protease:  background
HTLV-I protease is a homodimer composed of two 125-amino acid
monomers (Kobayashi et al., 1991).  The DNA and amino acid sequence of this
protease is shown in Figure 2.5.  The monomers each carry one catalytic
aspartic acid and fold together to form the active site and binding pockets.  Little
has been reported about the structure of HTLV-I protease, particularly the
binding pockets.  Knowledge of the binding pockets would provide useful
information about the electrostatic and steric contacts that are necessary for
substrate recognition and inhibitor binding.  The following summarizes current
hypotheses about the binding sites of HTLV-I protease.  These are based
principally on the two published theoretical structures.  A summary of the
substrate preferences of HTLV-I protease, and comparison to HIV-1 protease, is
given in Table 2.1 (Tözsér et al., 2000).
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 P   V   I   P   L     D   P   A   R   R     P   V   I   K   A
CCA GTT ATA CCG TTA   GAT CCC GCC CGT CGG   CCC GTA ATT AAA GCC  15
 Q   V   D   T   Q     T   S   H   P   K     T   I   E   A   L
CAG GTT GAC ACC CAG   ACC AGC CAC CCA AAG   ACT ATC GAA GCT CTA  30
 L   D   T   G   A     D   M   T   V   L     P   I   A   L   F
CTA GAT ACA GGA GCA   GAC ATG ACA GTC CTT   CCG ATA GCC TTG TTC  45
 S   S   N   T   P     L   K   N   T   S     V   L   G   A   G
TCA AGT AAT ACT CCC   CTC AAA AAT ACA TCC   GTA TTA GGG GCA GGG  60
 G   Q   T   Q   D     H   F   K   L   T     S   L   P   V   L
GGC CAA ACC CAA GAT   CAC TTT AAG CTC ACC   TCC CTT CCT GTG CTA  75
 I   R   L   P   F     R   T   T   P   I     V   L   T   S   C
ATA CGC CTC CCT TTC   CGG ACA ACG CCT ATT   GTT TTA ACA TCT TGC  90
 L   V   D   T   K     N   N   W   A   I     I   G   R   D   A
CTA GTT GAT ACC AAA   AAC AAC TGG GCC ATC   ATA GGT CGC GAT GCC  105
 L   Q   Q   C   Q     G   V   L   Y   L     P   E   A   K   G
TTA CAA CAA TGC CAG   GGC GTC CTG TAC CTC   CCT GAG GCA AAA GGG  120
 P   P   V   I   L    STOP
CCG CCT GTA ATC TTG   TGA
Figure 2.5.  HTLV-I protease DNA and amino acid sequence.  The residue and
corresponding codon in outline represent the catalytic aspartic acid.
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Position Preferred residues
HIV-1 protease HTLV-I protease
P4 Ser, Thr (small, polar) Thr, Val, Leu (small aliphatic side
chain)
P3 Phe, Leu (large hydrophobic,
aromatic)
Lys, Phe, Leu, Val, Ala
P2 Asn, Cys (small, polar) Val, Leu, Ile (small, hydrophobic)
P1 Leu, Phe (hydrophobic) Leu, Phe (hydrophobic)
P1’ Val, Leu, Ile, Phe (hydrophobic) Val, Leu, Pro (hydrophobic, smaller
than P1)
Table 2.1.  Comparison of substrate preferences of HTLV-I and HIV-1 proteases.
The S4 and S4’ binding sites are shallow, surface-exposed pockets.  In most
substrates, the residues at P4’ and P4 are hydrophobic, with proline being most
prevalent.  A variety of amino acids are tolerated at these sites; for example, the
capsid-nucleocapsid junction (CA/NC) has the polar residue threonine at P4.
However, N-terminal truncation is not well tolerated.  A synthetic nine-residue
substrate without a P5 residue showed reduced cleavage, while an eight-residue
substrate without a P4 residue exhibited no detectable cleavage (Tözsér et al.,
2000).
The S3 and S3’ binding sites are large and able to bind a variety of amino
acids.  Hydrophobic residues such as phenylanine and hydrophilic residues such
as lysine are accomodated here with similar catalytic efficiency (Tözsér et al.,
2000).  The S2 and S2’ binding sites are hydrophobic.  These sites are typically
occupied by small aliphatic hydrophobic residues such as valine, leucine, and
isoleucine.
27
The S1 binding site is hydrophobic and appears to be sterically hindered.
Leucine is the only residue that appears in this position in known natural
substrates.  Synthetic substrate studies have shown that phenylalanine is also
tolerated at this site; this is interesting considering that phenylalanine is much
larger than leucine, and it is common in HIV-1 protease substrates (Shuker et al.,
2003).   Steric hindrance is indicated by the exclusion of beta-branched residues
from the P1 position.  This may occur because the substrate backbone fits in a
narrow channel between Gly30 and Leu34 on opposite strands, excluding beta-
branched amino acids from the S1 site.  In contrast, the S1’ binding site prefers
proline, but the beta-branched residue valine is common here, as well as glycine
and serine.
2.5 Substrates and inhibitors of HTLV-I protease
HTLV-I protease has a unique substrate specificity.  The specificity of HTLV-I
protease restricts the protease from binding and cleaving non-viral peptide
sequences; however, it also prevents it from binding to inhibitors designed for
other proteases.  The native cleavage sites of HTLV-I protease have been










Table 2.2.  Native cleavage sites of HTLV-I protease.
HTLV-I protease is weakly inhibited by pepsin inhibitors, because it is also an
aspartic acid protease, and by HIV-1 inhibitors because of structural similarity.
Previous works have reported data for inhibition of HTLV-I protease with pepsin
inhibitors and HIV-1 inhibitors (Shuker et al., 2003); several effective inhibitors
are presented in Table 2.3.  Since HTLV-I protease has different substrate
specificity from pepsin and HIV-1 protease, it follows that HTLV-I will not be
effectively inhibited by compounds designed to target these proteases.  Previous
work shows that peptide-like compounds provide superior inhibition of all the
compounds studied to date.  In particular, JG-365 (Figure 2.6a), an HIV-1
protease inhibitor, is currently the most effective inhibitor, with Ki of 6.0 nM.  A
peptide-based, HTLV-I-specific inhibitor, shown in Figure 2.6b, was recently
reported (Akaji, Teruya, and Aimoto, 2003), with Ki of 38 nM.  However, few non-
peptide inhibitors have been tested with HTLV-I protease; MES13-099 (Figure
2.6c), with Ki of 243 nM, is the only one currently featured in the literature (Ding,













































































Figure 2.6. HIV-1 protease inhibitors. (a) MES13-099, (b) Compound 31 (Akaji et
al.), (c) JG-365
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CS-I-25 (pepsin) 19.2 N/A 7.2
CS-I-27 (pepsin) 0.22 N/A 142
MES13-099 (HIV-1) N/A 7 243
JG-365 (HIV-1) N/A 0.66 6
Table 2.3.  Effect of inhibitors on three aspartic acid proteases:  pepsin, HIV-1
protease, and HTLV-I protease.
2.6 HTLV-I protease expression, purification and assay
Several groups have reported cloning and purification of HTLV-I protease.
HTLV-I protease has been totally synthesized (Teruya et al., 2002), but it is also
common to express the protease in a bacterial system (Ding et al., 1998).
Previous work has reported yields up to 150 mg/L of culture by expression in E.
coli (Ha et al., 2002).  Mutations have also been tested and found to improve
protease stability.  In particular, mutation of Leu40 to Ile abolishes
autoprocessing at this position.  The native sequence around Leu40 (outlined
here) is MTVL/PIAL; VL/PI is present in other native cleavage junctions.
Substitution of Ile at the P1’ site inhibits cleavage.  Mutations to replace cysteines
at positions 90 and 109 do not affect catalytic activity (Louis, Oroszlan, and
Tozser, 1999).
Two methods of purification from cell culture have been reported.  The first
includes size exclusion chromatography followed by HPLC (Louis, Oroszlan, and
Tozser, 1999).  Other work reports functionalizing HTLV-I protease with a
polyhistidine tag in order to purify the protease by metal affinity chromatography
(Ding et al., 1998).  In both cases, purification under denaturing conditions is
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necessary, followed by refolding into buffer in which the protease is active.
Previous work also describes a method of determining protease concentration by
measuring absorbance at 280 nm (Ha et al., 2002).  Determination of protease
concentration is essential for kinetic experiments.
Two protease assays have been devised to determine kinetics and inhibition
of HTLV-I protease.  Analytical HPLC is commonly used to measure cleavage
(Ding, Rich, and Ikeda, 1998; Louis, Oroszlan, and Tozser, 1999; Tözsér et al.,
2000).  The other major method involves a fluorogenic substrate.  In this case, a
peptide matching a native cleavage sequence is functionalized with a fluorophore
and quencher.  The intact substrate self-quenches and emits a low background
fluorescence, a process called fluorescence resonance energy transfer or FRET
(Selvin, 1995).  Cleavage by the protease separates the fluorophore and
quencher, allowing detectable fluorescence.  Dabcyl and EDANS were attached
to the matrix-capsid junction PQVLPVMH to produce a fluorogenic substrate for
HTLV-I protease, which is depicted in Figure 2.7.  This substrate is excited at 340





































Figure 2.7.  Fluorogenic substrate for HTLV-I protease.  This substrate is based on the matrix-capsid junction,
PQVLPVMH (green), with fluorophore EDANS in blue, and quencher dabcyl in red.
Dabcyl EDANS
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2.7 Significance of present work
The present work develops more information of the enzyme kinetics of HTLV-
I protease.  In particular, the present work describes a new theoretical model of
the protease.  Experiments evaluate the effect of individual residues on substrate
binding and catalysis.  These data clarify the mechanism of substrate
recognition.  This information can be used to verify and refine structural models,
as well as to identify important binding interactions that can be exploited in
designing protease inhibitors. As with other retroviruses, the protease of HTLV-I
is essential for maturation of viral proteins.  Inhibition of the protease will slow or
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DEVELOPMENT OF A THEORETICAL MODEL AND FUNCTION OF THE TEN
C-TERMINAL RESIDUES
3.1 Similarity of HTLV-I protease to other retroviral proteases
HTLV-I protease is a member of the retroviral aspartic acid protease family.
As previously noted, these proteases have similar sequences and similar overall
folds and structures, but varying substrate specificity.  No experimental structure
of HTLV-I protease has been reported.
Structural information is essential to understanding substrate binding and
inhibitor design.  It is possible to use proteases with known structure as a
template for the prediction of HTLV-I’s structure by comparing their sequences.
The quality of the predicted structure depends on the homology or identity of the
proteases being studied.  The homology of retroviral proteases is presented in
Table 3.1 (Shuker et al., 2003).
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HTLV-I HTLV-2 BLV MuLV RSV HIV-1 HIV-2 SIV FIV EIAV
HTLV-I - 50% 36% 21% 25% 28% 29% 32% 23% 26%
HTLV-2 50% - 33% 25% 23% 26% 24% 26% 21% 25%
BLV 36% 33% - 27% 23% 24% 25% 25% 21% 26%
MuLV 21% 25% 27% - 21% 23% 24% 27% 25% 24%
RSV 25% 23% 23% 21% - 30% 26% 25% 26% 26%
HIV-1 28% 26% 24% 23% 30% - 48% 50% 25% 29%
HIV-2 29% 24% 25% 24% 26% 48% - 86% 24% 33%
SIV 32% 26% 25% 27% 25% 50% 86% - 22% 35%
FIV 23% 21% 21% 25% 26% 25% 24% 22% - 30%
EIAV 26% 25% 26% 24% 26% 29% 33% 35% 30% -
Table 3.1.  Homology, or percent identical sequence, of various retroviral proteases.
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3.2 Sequence alignment and generation of theoretical models
The software package MODELLER is able to generate sequence alignments
between proteins of known and unknown structure.  It can then use these
sequence alignments, with known structures as templates, to predict the
structure of the unknown protein (Fiser, Do, and Sali, 2000; Marti-Renom et al.,
2000; Sali and Blundell, 1993).  In the absence of an experimentally determined
structure of HTLV-I protease, MODELLER was to generate a theoretical model of
the protease for prediction of structural features.
A multiple alignment of several retroviral proteases is shown in Figure 3.1.  In
order to generate a structural model, two proteases with known structure were
selected:  RSV protease (PDB file 1BAI) (Wu et al., 1998), and HIV-1 protease
(1D4L) (Tyndall et al., 2002).  These proteases and structures were selected
based on homology and quality of the published structures.
The sequence alignment used by MODELLER, in MODELLER alignment file
format, is shown in Figure 3.2(a).  This file is essentially a machine-readable form
of the above noted multiple alignment, inlcuding only the sequences for HTLV-I,
HIV-1, and RSV proteases.  The MODELLER script used to generate the
theoretical model in shown in Figure 3.2(b).  This script reads the alignment file,
sets default parameters, and generates the model.
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 20                       40
                               |                        |
HTLV-I wt  PVIPLDPARRPVIKAQVDTQTSHP-K----TIEALLDTGADMTVLPIALFSSNT---
BLV        LSIPLA-RSRPSVAVYLSGPWLQPS-Q-NQ-ALMLVDTGAENTVLPQNWLVRDYPRI
RSV wt     LAMTMEHKDRPLVRVILTNTGSHPVKQRSVYITALLDSGADITIISEEDWPTDWPVM
RSV 1BAI   LAMTMEHKDRPLVRVILTNTGSHPVKQRSVYITALLDTGADDTVISEEDWPTDWPVM
HIV-1 wt   --PQITLWQRPLVTIKIGGQ----------LKEALLDTGADDTVLEEMSLPG-----
HIV-1 1D4L --PQITLWKRPLVTIRIGGQ----------LKEALLDTGADDTVIEEMNLPG-----
HIV-2 wt   --PQFSLWKRP-WTAYIEVQ----------PVEVLLDTGADDSIVAGIQLGD-----
FIV wt     VGTTTTLEKRPEILIFVNG----------YPIKFLLDTGADITILNRRDFQVKN---
                       60                 80
                       |                  |
HTLV-I wt  PLKN--TSVLGAGGQTQDHFKLTSLPVLIRLPFRTTPIVLTSCLVDTKNNWA-
BLV        PAA-----VLGAGGVSRNRYNWLQGPLTLALKPEGPFITIPKILVDTFDKWQ-
RSV wt     EAANPQIHGIGGGIPMRKSRDMIELGVINRDGSLERPLLLFPAVAMVRGS---
RSV 1BAI   EAANPQIHGIGGGIPVRKSRDMIELGVINRDGSLERPLLLFPLVAMTPVN---
HIV-1 wt   RWKP---KMIG-GIGG---FIKVRQYDQILVEICGHKAIGTVLIGPTPVN---
HIV-1 1D4L KWKP---KMIG-GIGG---FIKVRQYDQIPVEIXGHKAIGTVLVGPTPVN---
HIV-2 wt   NYVP---KIVG-GIGG---FINTKEIKNIEIKLN-KRVRATIMTGDTPIN---
FIV wt     SIENGRQNMIGVGGGKRGTNYINVHLEIRDENYKTQCIFGNVCVLEDNSLIQP
           100                120
           |                  |
HTLV-I wt  IIGRDALQQCQGVLYLPEAKGPPVIL
BLV        IIGRDVLSRLQASISIPEEVRPPMVG
RSV wt     ILGRDCLQGLGLRLTNL--------- Key
RSV 1BAI   ILGRDCLQGLGLRLTNL--------- Hydrophobic
HIV-1 wt   IIGRNLLTQIGCTLNF---------- Polar
HIV-1 1D4L IIGRNLLTQIGXTLNF---------- Basic
HIV-2 wt   VFGRNILTALGMSLNL---------- Acidic
FIV wt     LLGRDNMIKFNIRLVM----------
Figure 3.1.  Sequence alignment of several retroviral proteases.
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(a)
C; alignment in the PIR format
>P1;1d4l
























# A sample TOP file for fully automated comparative modeling
INCLUDE                                       # include MODELLER
routines
SET ALNFILE     = 'htlv-dimer.ali'  # input file w/ templates and
target
SET KNOWNS      = '1d4l' '1bai' # templates' PDB codes
SET SEQUENCE    = '3htl'                      # target code
SET ATOM_FILES_DIRECTORY = './' # directory with input atom files
SET STARTING_MODEL= 1
SET ENDING_MODEL= 5
SET OUTPUT_CONTROL = 1 1 1 1 2
CALL ROUTINE    = 'model'                # get alignment and a model
Figure 3.2.  Scripts used by MODELLER to generate the theoretical model.  (a)
Sequence alignment file.  (b) Script to generate the model from the alignment
and template PDB files.
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The theoretical model of the full-length, wild-type HTLV-I protease is shown
in Figure 3.3.  It is noted from the alignments that the last ten C-terminal residues
do not correspond to any portion of the sequence of HIV-1 protease or RSV
protease.  The ten C-terminal residues were omitted from the alignment, and the
MODELLER script was run again to generate a structure of the truncated
protease.  This structure is shown in Figure 3.4.  The core structure was not
significantly altered by the truncation, and data presented in Section 3.5 indicate
that it is not essential for catalysis.  The truncated protease structure was used to
prepare the published PDB model.
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Figure 3.3.  Theoretical model of full-length HTLV-I protease.
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Figure 3.4.  Theoretical model of C-terminal truncated HTLV-I protease.
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3.3 Docking a native substrate into the active site
Most experimentally determined structures of proteases are prepared using a
substrate or inhibitor in order to visualize binding.  Substrate binding contacts in
HTLV-I protease were demonstrated by docking the substrate TKVLVVQP in the
putative active site of HTLV-I protease, which was modeled using the commercial
software MOE (Chemical Computing Group, Montreal, Canada). The resulting
model was refined by software analysis.  Substrate design and docking work
were performed by Kelly Joy Dennison.  The final structure, with substrate, was
published in the Protein Data Bank as file 1O0J, and is represented in Figure 3.5.
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Figure 3.5.  HTLV-I protease with docked CA/NC substrate.  PDB file 1O0J.
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3.4 The ten C-terminal residues
It is clear from the sequence alignment presented in Figure 3.1 that the ten
C-terminal residues do not have a counterpart in the immune deficiency retroviral
protease sequences.  However, there is a corresponding C-terminal extension in
BLV protease.  Work on HTLV-I protease suggested that, while residues 121-125
could be deleted, residues 116-120 of the C-terminal extension were necessary
for catalysis (Hayakawa et al., 1992).  However, the authors did not perform an in
vitro assay of purified truncated protease and substrate, instead relying on
whole-cell protein analysis to detect cleavage product.  It is possible that
contaminants, including other cellular components or proteases, could have
confounded the result.  It is necessary to use purified protease and substrate to
eliminate the possibility of other reactions that might give similar results.
Previous work showed that the ten C-terminal residues of BLV protease are
not necessary for catalysis (Precigoux et al., 1993).  Further, the generated
model structure indicates that the C-terminal extension is not near enough to the
active site or putative binding sites to significantly influence catalytic activity.  In
order to determine the effect of the C-terminal extension, a mutant was prepared
that expressed only residues 1-115 of the protease.
3.5 Activity of full-length and truncated HTLV-I protease
A plasmid expressing L40I protease was prepared in previous work (Ha,
2001).  An expression plasmid carrying truncated protease, also called “wo10” or
“L40I-wo10”, was prepared by amplifying only the DNA encoding residues 1-115
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by PCR.  The PCR fragment was engineered to have NheI and XhoI restriction
sites and a stop codon at the 3’ end.  This fragment was digested and ligated to
similarly digested pET-28b plasmid.  The sequence of the resulting plasmid was
verified, and the plasmid was transformed into E. coli BL21(DE3) for expression.
Activity of full-length L40I protease and truncated L40I-wo10 protease was
assayed against the previously described fluorogenic substrate (Figure 2.7).  The
enzyme concentration was standardized to 50 nM.  Cleavage of varying
substrate concentrations was monitored by observing substrate fluorescence at
490 nm following excitation at 340 nm.  Eadie-Hosftee plots (Dowd and Riggs,
1965) of the resulting data are shown in Figures 3.6 (L40I) and 3.7 (L40I-wo10).
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Eadie-Hosftee plot for L40I













Figure 3.6.  Eadie-Hosftee plot of L40I kinetic data.
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Eadie-Hofstee plot for wo10


















Figure 3.7.  Eadie-Hoftstee plot of L40I-wo10 kinetic data.
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The analysis of the resulting data is summarized in Table 3.2.  The catalytic
efficiency, kcat/KM, was determined to be 593 ± 48 M
-1 s-1 for L40I, and 677 ± 54
M-1 s-1 for L40I-wo10.  While there is a marginal increase in catalytic efficiency of
the truncated L40I-wo10 protease, the margins of error overlap, indicating that
the difference may be due to experimental variability.  It is reasonable to
conclude from this data that the ten C-terminal residues play little role in catalytic
activity.
Protease kcat (s-1) KM (microM) kcat/KM (M-1 s-1)
L40I .00572 ± .000674 9.64 ± 1.73 593 ± 48
L40I-wo10 .00463 ± .000238 6.84 ± .575 677 ± 54
Table 3.2.  Summary of kinetic data for L40I and L40I-wo10 protease.
3.6 Discussion
The present work contrasts with previous work suggesting that residues 116-
120 of HTLV-I protease are necessary for catalysis; however, the authors of this
previous work did not perform an in vitro assay of purified truncated protease and
substrate, instead relying on whole-cell protein analysis to detect cleavage
product.  It is clear from the theoretical model that the C-terminal tail is distant
from the catalytic site and is probably not involved in catalysis.  Kinetic data show
that the truncated protease may have a slightly higher catalytic efficiency on the
tested substrate, but the increase in efficiency does not exceed the error bounds.
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MODIFYING THE SUBSTRATE SPECIFICITY OF HTLV-I PROTEASE
4.1 Identifying the substrate binding sites of HTLV-I protease
The active form of HTLV-I protease is composed of two identical
monomers, each of which contains one catalytic aspartic acid residue.  The
monomers bind to form the active site, which is composed of several pockets that
recognize certain amino acids in the substrate.  Previous studies have been
undertaken to identify which amino acids are preferred in certain positions in the
substrate (Mariani and Shuker, 2003; Tözsér et al., 2000).  However, little work
has been undertaken to identify the residues in HTLV-I protease that are involved
in substrate recognition.  Tözsér et al. prepared a theoretical model of HTLV-I
protease (Tözsér et al., 2000) and speculated on which residues at each binding
site might be important in recognizing substrate.  However, no attempt has been
made to validate which residues in the protease are important in substrate
binding.
4.2 Determining residues involved in binding by sequence alignment
The similarity between retroviral proteases makes it possible to align the
sequences to compare structural features.  For example, HIV-1 protease, the
most studied member of the retroviral protease family, can be used as a template
in the study of similar proteases.  The similarity between HIV-1 and RSV
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proteases was utilized to prepare a mutant form of RSV protease that was able
to process HIV-1 protease substrate (Wu et al., 1998).  A theoretical model of
HTLV-I protease has been previously reported (Tözsér et al., 2000).  This model
was developed by comparing the sequence of the published RSV protease S9
mutant (Wu et al., 1998), generating a model of HTLV-I protease using this
structure, and modeling the substrate KVL/VVQP in the active site.  However,
this model was not deposited in the Protein Data Bank, and it is not readily
available for examination.
In order to compare substrate specificity of HTLV-I protease with that of
HIV-1 protease, a published alignment was compared to the HIV-1 and RSV
protease alignment used by Wu et al. to prepare the mutant RSV protease.  The
alignment that was used to prepare the PDB model 1O0J was also compared to
the HIV-RSV alignment.
The multiple alignment of HIV-1 protease, RSV protease, and the two
HTLV-I protease alignments is shown in Figure 4.1.  Residues highlighted in the
RSV protease line were mutated to the residues at corresponding positions in
HIV-1 protease.  Based on this alignment, corresponding residues in HTLV-I
protease were identified.  The residues in HTLV-I protease that align with
residues identified to be important for specificity in RSV protease were mutated










Figure 4.1.  Multiple alignment of RSV protease (RSVwt), HTLV-I protease (Shuker alignment: S), HTLV-I protease
(Tözsér alignment: T), HIV-1 protease.  Residues in yellow in RSV protease were mutated by Wu et al. to the
corresponding residues in HIV-1 protease.
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4.3 Preparation of mutants
Mutations were performed by overlap extension (Ho et al., 1989; Horton et
al., 1989).  This two-step PCR-based protocol allows the preparation of single- or
multiple-mutant DNA inserts that are then digested and ligated into an expression
plasmid.  This procedure requires four primers:  a 5’ primer matching the target
gene, a 3’ primer matching the target gene, and two complementary primers
carrying the mutation flanked by 12-15 bases matching the gene sequence on
either side.  The 5’ and 3’ primers typically have restriction sites to facilitate
insertion into a plasmid.  In the first reaction, two separate amplifications are
performed to prepare two fragments:  the 5’ half of the gene with a 3’ mutation,
and the 3’ half of the gene with a 5’ mutation.  The mutated ends of the halves
correspond such that when the two halves are amplified in the presence of 5’ and
3’ end primers, the mutated sections anneal, and the complete gene with
mutation is amplified.  Overlap extension is summarized in Figure 4.2.  This
process was repeated multiple times with different primers to produce genes with
multiple mutations.  The mutated gene was digested with restriction enzymes
and ligated to a similarly digested plasmid, producing a construct to express the
mutant gene.
Preliminary work in which percent activity was determined was performed
by incubating protease samples at 37°C with HIV-1 substrate H-2930 (Molecular
Probes), a FRET substrate that is excited at 340 nm and emits at 490 nm upon
cleavage. Percent activity was calculated by dividing the initial rate observed for
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each mutant by the initial rate observed for HIV-1 protease.  Percent activity data




Reaction 1, Step 1 PCR:
-F1->
------------AAA------------
         <--CCC-Mut1
Reaction 2, Step 1 PCR:
       Mut2-GGG-->
------------AAA------------
                      <-R1-
Products of step 1 are purified to remove template.
Step 2 PCR, part 1 – mutated halves overlap and anneal:
------------CCC---
          --GGG------------
Fill-in by Vent DNA polymerase yields:
------------CCC------------
------------GGG------------





                      <-R1-
Step 2 is purified, digested, and ligated to yield a
construct.
Figure 4.2.  Mutation by overlap extension.  Fragments shown as arrows, e.g.
–F1->, are primers.
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Protease variant Percent activity
HIV-1 protease 100%
HTLV-I protease, alternate Shuker 50%
HTLV-I protease, Shuker 30%
HTLV-I protease, Tözsér 5%
HTLV-I protease, wild-type ND
Table 4.1.  Preliminary kinetic data for specificity mutants.  These data were
obtained independently from the data used for Michaelis-Menten analysis.
4.4 Activity of HIV-1 substrate-specific mutant based on Tözsér alignment
The mutant form of HTLV-I protease based on Tözsér et al. alignment
carries the following mutations: M37D, D65V, V92L, N96T, N97P, W98V, and
A99N.  These mutations are depicted in Figure 4.3(a).  This mutant was
incubated with a nitrophenylalanine-containing HIV-1 protease substrate.  The
rate of catalysis was determined by monitoring the absorbance at 290 nm and
correcting for background variation.
4.5 Activity of HIV-1 substrate-specific mutant based on Shuker alignment
The mutant form of HTLV-I protease based on Shuker alignment carries
the following mutations: M37D, T63V, C90L, K95P, and N96V.  These mutations
are depicted in Figure 4.3(b). This mutant was incubated with a
nitrophenylalanine-containing HIV-1 protease substrate.  The rate of catalysis
was determined by monitoring the absorbance at 290 nm and correcting for
background variation.
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Figure 4.3.  Mutations made based on different alignments.  Target residues are
bold with mutations above or below the parent sequence.  (a) Mutations based
on Tözsér alignment; (b) mutations based on Shuker alignment; (c) mutations
based on best fit regions in both alignments.
4.6 Activity of HIV-1 substrate-specific mutant based on alternate Shuker
alignment
Review of the multiple alignment shows a two-residue variance between
the Shuker and Tözsér alignments around Gly58.  This difference appears to be
caused by a variance in gaps between the two alignments.  However, this
alignment affects whether Thr63 or Asp65 should be aligned with the
corresponding residue in RSV protease.  This variance in alignment may alter the
specificity of the mutant forms.  In order to assess which alignment is more valid,
a third mutant was prepared based on the Shuker alignment, but incorporating
D65V rather than T63V.  The revised Shuker alignment is shown in Figure 4.4.
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HTLV-ALT PVIPLDPARRPVIKAQVDTQT---S-HP--KTIEALLDTGADMTVLPIALFSSN-----TP-LKN
HIV-1    PQITLW--KRPLVTIKIG-----------GQLKEALLDTGADDTVIEE--MS---LPGRW-KPK-
HTLV-ALT -TSVLGAGGQTQDHFK-LTSLPVLIR--LPFRTTPIVLTSCLVDTKNNWAIIGRDALQQCQGVLYLPEAKGPPVIL
HIV-1    --MIGGIGGFIKV-RQY-DQIIIEIC-----GH-KAIGTVLVGPTPVN--IIGRNLLTQIGCTLNF----------
Figure 4.4.  Revised alignment of HTLV-I protease and HIV-1 protease.  The yellow highlight indicates the similar region
that was targeted in adjusting the alignments about Gly58 in the HTLV-I sequence.  The green highlight shows Thr63 and
Asp65 in the HTLV-I sequence and the corresponding valine in the HIV-1 sequence.
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The mutant form of HTLV-I protease based on the alternate Shuker
alignment carries the following mutations: M37D, D65V, C90L, K95P, and N96V.
These mutations are depicted in Figure 4.3(c). This mutant was incubated with a
nitrophenylalanine-containing HIV-1 protease substrate.  The rate of catalysis
was determined by monitoring the absorbance at 290 nm and correcting for
background variation.
4.7 Summary and Discussion
The kinetic data from all HIV-1 substrate specific HTLV-I protease
mutants, wild-type HIV-1 protease, and wild-type HTLV-I protease are
summarized in Table 4.2.
Mutant kcat (s-1) KM (microM) kcat/KM (mM-1 s-1)
HIV-1 protease (Toth





3.6x10-3 ± 2.9x10-4 64 ± 10 0.056 ± 0.0045
HTLV-I protease:
Shuker mutant (S) 1.6x10
-3 ± 1.3x10-4 52 ± 8 0.031 ± 0.0025
HTLV-I protease:
Tözsér mutant (T) 4.5x10
-4 ± 4.4x10-5 39 ± 8 0.012 ± 0.0011
HTLV-I protease:
wild type Not detected Not detected Not detected
Table 4.2.  Summary of kinetic data from variants of HTLV-I protease and HIV-1
protease on HIV-1 protease substrate.
In terms of kcat/KM, or overall catalytic efficiency, it is clear that the
specificity mutant based on the alternate Shuker alignment has the highest
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efficiency at 0.056 mM-1 s-1, followed by the mutant based on the Shuker
structure alignment at 0.031 mM-1 s-1, followed by the mutant based on the
Tözsér alignment at 0.012 mM-1 s-1.  The increase in kcat is in line with preliminary
percent activity data derived from a fluorescence experiment.  However, the
binding constant, KM, increases with efficiency, indicating less specific binding
despite increasing turnover, kcat.  The apparent decrease in binding constant
could indicate a general decrease in specificity, rather than specificity to HIV-1
protease substrate.  Nonetheless, this study indicates that certain residues are
significant in binding substrate for catalysis, and that these residues can be
identified through sequence alignment.  The sequence alignments prepared in
the present work better indicate which residues are significant in binding.  These
results further indicate that the structural model based on the Shuker alignment is
a better representation of HTLV-I protease than the structural model based on
the Tözsér alignment.  With additional knowledge of the residues that are
involved in specificity, we will be able to develop inhibitors that have contacts
matching the pattern in the active site of HTLV-I protease.
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ALANINE SCAN OF HTLV-I PROTEASE
5.1 Purpose of alanine scan
Knowledge of which residues in the sequence of HTLV-I protease contribute
to substrate binding is essential to understanding the structure and function of
this protease.  Determining which steric and electrostatic contacts are needed for
catalysis can also help in the design of protease inhibitors; for example,
identifying positive, negative, and hydrophobic contacts at each protease subsite
allows rational selection of residues in peptide-based inhibitors.  An alanine scan
is an important diagnostic tool for identifying residues involved in catalysis
(Cunningham and Wells, 1989).  In this technique, a single residue is mutated to
alanine, and the kinetic parameters of the resulting mutant are evaluated.
Alanine is chosen because it has the smallest side chain other than glycine, but
unlike glycine, it is chiral and maintains the conformation of the backbone.
Several residues believed to be important in binding are mutated to determine
the contribution of these residues to the catalytic activity of the protease.  In the
case of HTLV-I protease, several residues were hypothesized to be important in
binding based on the theoretical structure.  The following residues were studied
in the present work: Arg10, Leu30, Thr94, Lys95, Asn96, Trp98, and Ile100.
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Figure 5.1.  Positions of residues selected for alanine scan.  Green and blue
structure is protease; blue residues were mutated to alanine.  Red structure is
the CA/NC substrate.
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5.2 Preparation of alanine mutants
Single alanine mutants of L40I HTLV-I protease were prepared by overlap
extension (Ho et al., 1989; Horton et al., 1989).  This process was summarized in
Figure 4.2.  The following residues were mutated to alanine: Arg10, Leu30,
Thr94, Lys95, Asn96, Trp98, and Ile100.  The position of these residues in the
theoretical structure is shown in Figure 5.1.  Each construct was transformed into
E. coli BL21(DE3) cells, and the resulting mutant protease was expressed and
purified as described.  Kinetic studies were performed using an analog of the
matrix-capsid substrate, APQVL(Nph)VMHPL, where Nph is 4-
nitrophenylalanine.  The substrate is shown in Figure 5.2.  The activity of L40I




























































Figure 5.2.  Substrate used in alanine scan kinetic study.
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5.3 Results and discussion
Kinetic data for all alanine mutants as well as L40I are summarized in Table
5.1.  Inferences about structural significance are based on the theoretical model,
PDB file 1O0J, presented in Chapter 3.  The reference L40I protease had kcat/KM
of 63.5 M-1 s-1.
Mutant kcat (s-1) KM (microM) kcat/KM (M-1 s-1)
L40I 2.74 x 10-3 43.2 63.5
R10A 7.18 x 10-3 61.6 117
L30A 5.72 x 10-3 71.6 79.9
T94A 3.01 x 10-3 111 27.2
K95A 9.36 x 10-3 73.6 127
N96A 6.03 x 10-3 70.3 85.7
W98A 2.96 x 10-3 8.33 355
I100A 4.43 x 10-3 43.3 102
Table 5.1.  Summary of kinetic data of alanine mutants.
Mutating Arg10 to alanine increased kcat/KM to 117 M
-1 s-1, which is due to a
significant increase in kcat and a small increase in KM.  Arg10 appears to lie in the
entrance to the active site channel and may provide a steric barrier and
electrostatic contact to the substrate; replacing Arg10 with alanine appears to
remove the steric barrier, allowing faster turnover.  Leu30 lies very near the
catalytic aspartic acid, Asp32, and probably contributes to the overall
hydrophobicity of S1 and S1’.  The position and size of Leu30 probably plays a
significant role in restricting the type of residue that can bind in S1 and S1’.
However, mutating Leu30 to alanine does not significantly change the efficiency
of the enzyme; the kcat/KM of this mutant is 79.9 M
-1 s-1.  Other nearby residues,
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notably the adjacent Leu31, may play a stronger role in selectivity in the active
site, or the position of surrounding residues such as Leu31 may change to yield a
similar effect.
Residues 94-100 lie on a loop on the interior of the protease.  As noted in
Chapter 4, residues in this loop play a significant role in selectivity.  For example,
mutation of Thr94 decreases the catalytic efficiency of the protease to kcat/KM of
27.2 M-1 s-1.  Most of the decrease in efficiency is due to an increase in KM,
indicating weaker binding of the substrate. Thr94 may play a role in stabilizing
the protease structure in the active site region.  In the theoretical model, the
hydroxyl group on the side chain of Thr94 lies near the backbone carbonyl
oxygen of the P1 Leu.  In the initial step of catalysis, the negatively charged
oxygen of the catalytic aspartic acid attacks the carbonyl carbon.  It is possible
that the hydroxyl side chain of Thr94 stabilizes the partial negative charge on the













Figure 5.3.  Stabilization of the backbone carbonyl oxygen by Thr94 prior to
cleavage between Leu and Val.
Lys95 is a bulky residue with a charged amino group.  Mutating this residue
leads to a substantial increase in turnover, with overall kcat/KM of 127 M
-1 s-1.  The
lysine side chain must move to accommodate substrate; therefore, removing the
side chain results in faster binding.  However, binding is slightly less specific as
measured in terms of KM.  Mutation of Asn96 to alanine has little effect on
catalytic activity, suggesting that this residue plays little role in structure or
catalysis.  Mutation of the bulky residue Trp98 to alanine dramatically improves
the efficiency to kcat/KM of 355 M
-1 s-1.  Most of the change is in KM, indicating
tight binding of the substrate.  However, this is likely due to the chosen substrate,
which has nitrophenylalanine at P1’.  The nitrophenylalanine likely interacts with
the aromatic ring of Trp98, and removal of Trp98 apparently eliminates this steric
constraint.  Ile100 appears to contribute to the hydrophobic surface around S1
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and S1’.  The contribution of Ile100 is small; mutating Ile100 to alanine increases
efficiency to kcat/KM of 102 M
-1 s-1, with all of the effect due to an increase in kcat.
If Ile100 were present, the side chain would probably bend slightly in the process
of binding; if this conformational change were not needed, as is the case in the
alanine mutant, turnover increases slightly as observed.
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CHAPTER 6
CONCLUSIONS AND FUTURE WORK
HTLV-I was discovered in the early 1980’s in Japanese and American
patients with cutaneous T-cell lymphoma (Gallo, 1996; Gessain, 1996).  The
protease of this retrovirus has been isolated and characterized (Nam and
Hatanaka, 1986).  However, no effective treatments exist that target the virus.
Although HTLV-I relies on reverse transcriptase to transcribe its genome, reverse
transcriptase inhibitors designed for HIV-1 infection show little therapeutic
benefit.  Protease inhibitors have been reported (Shuker et al., 2003), but there
are no clinically approved protease inhibitors for the treatment of HTLV-I-related
illness.
In the present work, information about the structure of HTLV-I protease is
determined.  A new sequence alignment with HIV-1 protease is described, and a
theoretical model based on this alignment is presented, showing the structure of
the protease with bound natural substrate.  It was also determined that the ten C-
terminal residues do not contribute to catalytic activity.
Sequence alignment among several retroviral proteases made it possible
to identify residues that are important in specificity.  Comparison of the
sequences of RSV, HIV-1, and HTLV-I proteases allowed identification of several
residues that are important in binding substrate.  Mutation of residues in HTLV-I
protease to the corresponding residues in HIV-1 protease yielded a form of
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HTLV-I protease that could cleave HIV-1 protease substrate.  This experiment
also resulted in the selection of a different alignment of HIV-1 and HTLV-I
proteases.  Mutations prepared based on this new alignment yielded a protease
that processed HIV-1 protease substrate more efficiently, indicating that this
alignment corresponded better with HIV-1 protease.
An alanine scan was performed to elucidate the function of several
residues.  These residues were selected based on their position in the theoretical
structure.  Based on these results, we determined that Thr94 is significant in
catalysis, and several other tested residues play some role in catalysis.  In
contrast, Asn96 appears to play little role in catalysis.  No single residue in the
test set was shown to be absolutely necessary for catalysis.
Future work on HTLV-I protease will focus on two key projects.  First, the
structure of the protease should be experimentally determined.  This will confirm
the studies described here, and give substantial information relating to the
structure of the protease and how it binds substrate and inhibitor.  Second,
peptide- and non-peptide-based inhibitors of the protease should be developed.
A collaboration exists between our group and the CDC, and it is hoped that this
work will lead to protease inhibitors that are effective against infected cells in
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Preparation of plasmids expressing HTLV-I protease without 10 C-terminal
residues.  The gene for HTLV-I protease was cloned from the K30 strain of
HTLV-I, which was prepared by Thomas Kindt (Mulligan and Berg, 1981; Zhao et
al., 1995).  A plasmid expressing HTLV-I protease with L40I mutation, called
pPR203, was prepared in previous work (Ha, 2001).  For the present work, a
plasmid expressing protease without the last ten amino acids was prepared.
This was accomplished by PCR amplification of pPR203 using primers to clone
residues 1-115 with NheI restriction site at the 5' end and XhoI restriction site at
the 3' end.  PCR amplification was carried out using Vent DNA polymerase, Vent
polymerase buffer and dNTP mix (NEB), and a temperature profile of 95°C for 1
minute, 55°C for 1 minute, 72°C for 1 minute, repeated 30 times.  The PCR-
prepared insert was digested with NheI and XhoI (NEB) under buffer conditions
recommended by New England Biolabs.  The plasmid pET-28b was similarly
digested.  The digested insert was ligated to digested pET-28b using T4 DNA
ligase (NEB), but using NEBuffer 2 (10 mM Tris-HCl, 50 mM NaCl, 10 mM
MgCl2, 1 mM DTT, pH 7.9) plus fresh DTT and ATP solutions to match the
concentration of DTT and ATP in NEB T4 buffer (50 mM Tris-HCl, 10 mM MgCl2,
10 mM DTT, 1 mM ATP, 25 ug/mL BSA, pH 7.5).  The ligation was carried out at
20°C for 3 hours.  The ligated plasmid was transformed as noted below, and the
sequence was verified by the Sanger dideoxy method at the Georgia Tech
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Biology Core Facility.
Preparation of mutant forms of HTLV-I protease.  For specificity and alanine scan
mutants, mutations were performed by overlap extension (Ho et al., 1989; Horton
et al., 1989).  For alanine scan mutants, only one overlap extension was
performed, while for specificity mutants, the process was repeated until all
targeted residues were changed.  PCR primers encoding 5' (with NheI site) and
3' ends (with XhoI site) and mutations were synthesized by Integrated DNA
Technologies.  PCR amplification was performed in two steps as described in
literature, with a temperature profile of 95°C for 1 minute, 55°C for 1 minute,
72°C for 1 minute for 30 cycles in the second overlap step.  The mutant insert
and pET-28b were digested and ligated as above.  The ligated plasmid was
transformed as noted below, and the sequence was verified by the Sanger
dideoxy method at the Georgia Tech Biology Core Facility.
Transformation of cells with HTLV-I protease constructs.  Competent E. coli cells
were thawed on ice.  A small volume, 1-5 uL, of plasmid solution was added to
the cells.  The cells were allowed to stand on ice for 30 minutes.  The cells were
heat shocked at 42°C for 45 seconds.  The cells were chilled on ice for 1 minute.
The cells were transferred to cool antibiotic-free LB or SOC broth, at least 5
times the volume of cells.  This culture was grown at 37°C for 1 hour, and 100 uL
of the culture was streaked on an LB agar plate with antibiotic corresponding to
the plasmid.  The agar plate was incubated for 37°C overnight.  Alternatively, 100
uL of the antibiotic-free culture was transferred to 5 mL LB broth with the
appropriate antibiotic.  This liquid culture was then incubated overnight at 37°C.
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Preparation of frozen stocks on transformed cells.  Transformed cells were
allowed to grow in antibiotic-labeled liquid media and incubated until the culture
was turbid, at least 8 hours.  One mL of culture was transferred to a labeled glass
vial.  One mL of 7% v/v DMSO in dH2O was added to the culture.  This mixture
was frozen at -70°C immediately.  Frozen stocks were reconstituted by scraping
the frozen stock and transferring the ice to 5 mL of antibiotic-labeled LB broth
and incubating overnight.
Expression of HTLV-I protease.  All forms of HTLV-I protease were expressed in
the same manner.  E. coli BL21(DE3) cells transformed with an HTLV-I
expression plasmid were grown in 5 mL LB broth at 37°C overnight.  Between 1
and 5 mL of the overnight culture was transferred to a larger volume, and the
culture was grown at 37°C to an OD600 of 0.6.  The culture was induced to
express protease by the addition of IPTG to a final concentration between 0.5-1
mM.  The culture was then grown an additional 2 to 3 hours.  The cells were
harvested by centrifugation at 10,000g  for 10 minutes.  The pellet was
resuspended in Buffer A (20 mM Tris-HCl, 500 mM NaCl, 5 mM imidazole),
sonicated, and centrifuged at 10,000g  for 10 minutes.  The pellet was
resuspended in Buffer B (20 mM Tris-HCl, 500 mM NaCl, 6 M urea, 5 mM
imidazole), sonicated, and allowed to stand on ice for at least 30 minutes, but not
more than 2 hours.  This suspension was then centrifuged at maximum speed for
30 minutes.  The supernatant was collected for purification, and the pellet was
discarded.
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Purification of HTLV-I protease.  All forms of HTLV-I protease were purified by
the same method.  A column was packed with an amount of His-Bind nickel
affinity chromatography resin (Novagen).  The bed volume (hereafter, “volume”)
was noted and used as a multiplier to determine the amount of each buffer to use
in subsequent step.  The column is equilibrated with 5 volumes ddH2O, 5
volumes 50 mM NiSO4, and 5 volumes Buffer B.  The supernatant from the
expression was then loaded.  The supernatant was followed by 10 volumes of
Buffer B and 6 volumes of Buffer C (20 mM Tris-HCl, 500 mM NaCl, 6 M urea, 20
mM imidazole).  HTLV-I protease was eluted by addition of 5 volumes of Buffer
D250 (20 mM Tris-HCl, 500 mM NaCl, 6 M urea, 250 mM imidazole) and
collected in 1 mL fractions of eluent.  The column was washed with 5 volumes of
strip buffer.  As needed, the column was cleaned by the method noted in the
Novagen purification handbook.  Column fractions were assayed for protein
content and purity by SDS-PAGE gel.  In some cases, presence of protein in the
fractions was tested by Bio-Rad dye assay (10 uL dye + 30 uL water + 10 uL
eluent fraction on Parafilm).  Fractions that turned blue were retained.  Purified
HTLV-I protease was then dialyzed to 100 mM acetic acid at 4°C overnight.
Following dialysis, protease concentration was determined by absorbance at 280
nm.
Assay of HTLV-I protease with and without the ten C-terminal residues.  This
work was performed by Victoria Mariani.  Briefly, purified L40I (full-length) and
L40I-wo10 (truncated) constructs were expressed and purified as described.
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These constructs were assayed on varying concentrations of Dabcyl-
PQVLPVMH-EDANS, a FRET substrate that absorbs at 340 nm and fluoresces
at 490 nm on cleavage.  Cleavage was monitored at 37°C in a PTI
spectrofluorophotometer.  Initial rates were determined from the fluorescence
data, and kinetic parameters were determined by Eadie-Hofstee plot (Dowd and
Riggs, 1965).
Assay of HTLV-I protease specificity mutants against HIV protease substrate.
The assay was performed with a fixed concentration of protease in 50 mM
sodium acetate pH 5.2, 10% (v/v) glycerol, and varied concentrations of
nitrophenylalanine-containing HIV-1 protease substrate H-5930 (Sigma) in
DMSO.  The rate of reaction was obtained by setting up reaction mixtures on a
96-well Costar microtiter plate, incubating at 37°C and monitoring the
absorbance at 290 nm in a Molecular Devices SpectraMax Plus384 plate reader.
Reaction mixtures with no protease added were also monitored as a control and
to determine background effects.  Initial rates were determined from the slopes of
the absorbance curves, and kinetic parameters were calculated by Eadie-Hofstee
plot.
Assay of single alanine mutants of HTLV-I protease against HTLV-I protease
substrate.  The assay was performed with a fixed concentration of protease and
varied concentrations of HTLV-I protease substrate APQVL(Nph)VHMPL
(Synpep) in 50 mM sodium acetate, pH 5.2.  Activity was measured by
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